Johnny WolfA treatment that genetically modifies a patient's own white blood cells to attack the cancer multiple myeloma had "impressive" results in an early clinical trial, experts say. This CAR-T targets a protein found in multiple myeloma cells called B-cell maturation antigen, or BCMA. Another 8 patients had a very good partial response, meaning that signs of cancer in their blood almost vanished. Bluebird looked to see if patients with higher levels of the BCMA protein in their cancer responded better to the treatment. Still, CART treatments, which require white blood cells to be removed from a patient, altered, and returned, are complicated and time-consuming.

Source: Forbes June 01, 2018 22:07 UTC